Mouse Disabled1 (DAB1) is a Nucleocytoplasmic Shuttling Protein
Overview
Authors
Affiliations
Disabled1 (DAB1) is an intracellular mediator of the Reelin-signaling pathway and essential for correct neuronal positioning during brain development. So far, DAB1 has been considered a cytoplasmic protein. Here, we show that DAB1 is subject to nucleocytoplasmic shuttling. In its steady state, DAB1 is mainly located in the cytoplasm. However, treatment with leptomycine B, a specific inhibitor of the CRM1 (chromosomal region maintenance 1)-RanGTP-dependent nuclear export, resulted in nuclear accumulation of DAB1. By using deletion or substitutional mutants of DAB1 fused with enhanced green fluorescent protein, we have mapped a bipartite nuclear localization signal and two CRM1-dependent nuclear export signals. These targeting signals were functional in both Neuro2a cells and primary cerebral cortical neurons. Using purified recombinant proteins, we have shown that CRM1 binds to DAB1 directly in a RanGTP-dependent manner. We also show that tyrosine phosphorylation of DAB1, which is indispensable for the layer formation of the brain, by Fyn tyrosine kinase or Reelin stimulation did not affect the subcellular localization of DAB1 in vitro. These results suggest that DAB1 is a nucleocytoplasmic shuttling protein and raise the possibility that DAB1 plays a role in the nucleus as well as in the cytoplasm.
Rodriguez-Rodriguez P, Wang W, Tsagkogianni C, Feng I, Morello-Megias A, Jain K bioRxiv. 2025; .
PMID: 39803521 PMC: 11722323. DOI: 10.1101/2024.12.31.630881.
Annevelink C, Westra J, Sala-Vila A, Harris W, Tintle N, Shearer G J Nutr. 2023; 154(5):1640-1651.
PMID: 38141771 PMC: 11347816. DOI: 10.1016/j.tjnut.2023.12.035.
Demir R, Deveci R Amino Acids. 2023; 55(6):757-767.
PMID: 37067567 DOI: 10.1007/s00726-023-03266-5.
Heterozygous Null Mutation Disrupts Neocortical and Hippocampal Development.
Honda T, Hirota Y, Nakajima K eNeuro. 2023; 10(4).
PMID: 36941061 PMC: 10089055. DOI: 10.1523/ENEURO.0433-22.2023.
Inoue S, Hayashi K, Fujita K, Tagawa K, Okazawa H, Kubo K J Neurosci. 2018; 39(4):678-691.
PMID: 30504273 PMC: 6343645. DOI: 10.1523/JNEUROSCI.1634-18.2018.